GNE-0439 is a novel selective Nav1.7 inhibitor with potential applications in the treatment of pain disorders; it shows high selectivity over Nav1.5 and effectively inhibits the mutant N1742K channel, suggesting its utility in studying or targeting voltage-gated sodium channel-related pathologies.